- Home
- APRE vs FLGC Comparison
APRE vs FLGC Comparison
Compare APRE & FLGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APRE | FLGC |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 7.6M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | APRE | FLGC |
|---|---|---|
| Price | $0.94 | $7.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 77.2K | 63.6K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $488,239.00 | ★ $57,609,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.71 |
| 52 Week Low | $0.84 | $5.86 |
| 52 Week High | $4.65 | $47.00 |
Technical Indicators
Market Signals| Indicator | APRE | FLGC |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 40.78 |
| Support Level | $0.91 | $5.86 |
| Resistance Level | $1.02 | $7.55 |
| Average True Range (ATR) | 0.05 | 1.05 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 44.44 | 25.27 |
Price Performance
Historical ComparisonAbout APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.